查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1969872

全球流感疫苗市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Influenza Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

流感疫苗市场预计将从 2025 年的 95.8 亿美元成长到 2034 年的 178.8 亿美元，2026 年至 2034 年的复合年增长率为 7.18%。

由于人们对季节性流感预防的意识不断提高，全球流感疫苗市场持续稳定成长。世界各国政府和卫生组织每年都会进行疫苗接种宣传活动，以减少与流感相关的住院和死亡病例。流感病例的增加和大流行的风险促使医疗卫生系统加强疫苗接种计划。疫苗研发技术的进步，包括细胞培养疫苗和重组疫苗，也推动了市场扩张。

推动疫苗接种率上升的主要因素之一是医疗保健和疫苗接种率的日益重视。老年人、儿童和慢性疾病患者等高风险族群需要定期接种流感疫苗。政府拨款、公共卫生措施以及低温运输基础设施的改善正在加强疫苗供应系统。此外，製药公司也加大研发投入，以提高疫苗的有效性和产能。

未来几年，随着全球疫苗接种率的提高，市场预计将稳定成长。新兴经济体医疗保健覆盖范围的扩大将创造新的成长机会。通用流感疫苗的创新和快速生产方法的开发将进一步增强该行业实力。随着全球卫生基础设施建设成为优先事项，全球流感疫苗市场预计将保持稳定、长期的成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球流感疫苗市场：依疫苗类型划分

  • 市场分析、洞察与预测
  • 灭活疫苗
  • 减毒活病毒疫苗

第五章：全球流感疫苗市场：依适应症划分

  • 市场分析、洞察与预测
  • 四价
  • 三价

第六章：全球流感疫苗市场：依年龄组别划分

  • 市场分析、洞察与预测
  • 儿童
  • 成人

第七章：全球流感疫苗市场：依给药途径划分

  • 市场分析、洞察与预测
  • 注射
  • Nasal Spray

第八章 全球流感疫苗市场：依通路划分

  • 市场分析、洞察与预测
  • 医院和药房
  • 向政府和机构供应
  • 其他的

第九章 全球流感疫苗市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第十章 竞争格局

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第十一章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • GSK Plc
    • Pfizer Inc
    • Vaxess Technologies Inc
    • Merck & Co. Inc
    • Viatris Inc
    • Osivax
    • AstraZeneca Plc
    • Sinovac Biotech Ltd
    • CSL Limited
    • Emergent BioSolutions Inc
    • Emergex Vaccines Holding Ltd
简介目录
Product Code: VMR112110532

The Influenza Vaccine Market size is expected to reach USD 17.88 Billion in 2034 from USD 9.58 Billion (2025) growing at a CAGR of 7.18% during 2026-2034.

The Global Influenza Vaccine Market is witnessing consistent growth due to increasing awareness about seasonal flu prevention. Governments and health organizations worldwide conduct annual vaccination campaigns to reduce flu-related hospitalizations and deaths. Rising cases of influenza outbreaks and the risk of pandemics are pushing healthcare systems to strengthen immunization programs. Technological advancements in vaccine development, including cell-based and recombinant vaccines, are also supporting market expansion.

One of the main drivers is the growing emphasis on preventive healthcare and immunization coverage. High-risk groups such as elderly individuals, children, and patients with chronic diseases require regular flu vaccination. Government funding, public health initiatives, and improved cold chain infrastructure are enhancing vaccine distribution. Additionally, pharmaceutical companies are investing in research and development to improve vaccine effectiveness and production capacity.

In the coming years, the market is expected to grow steadily with improved global vaccination rates. Expanding healthcare access in emerging economies will create new growth opportunities. Innovations in universal flu vaccines and faster production methods may further strengthen the industry. As global health preparedness becomes a priority, the influenza vaccine market is likely to maintain stable and long-term growth worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

  • Inactivated
  • Live Attenuated

By Indication

  • Quadrivalent
  • Trivalent

By Age Group

  • Pediatric
  • Adult

By Route of Administration

  • Injection
  • Nasal Spray

By Distribution Channel

  • Hospitals & Pharmacies
  • Government & Institutional Supply
  • Others

COMPANIES PROFILED

  • GSK plc, Pfizer Inc, Vaxess Technologies Inc, Merck Co Inc, Viatris Inc, Osivax, AstraZeneca plc, Sinovac Biotech Ltd, CSL Limited, Emergent BioSolutions Inc, Emergex Vaccines Holding Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL INFLUENZA VACCINE MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Vaccine Type
  • 4.2. Inactivated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Live Attenuated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL INFLUENZA VACCINE MARKET: BY INDICATION 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Indication
  • 5.2. Quadrivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Trivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL INFLUENZA VACCINE MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Age Group
  • 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL INFLUENZA VACCINE MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

  • 7.1. Market Analysis, Insights and Forecast Route Of Administration
  • 7.2. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.3. Nasal Spray Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL INFLUENZA VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Hospitals & Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.3. Government & Institutional Supply Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL INFLUENZA VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.2.1 By Vaccine Type
    • 9.2.2 By Indication
    • 9.2.3 By Age Group
    • 9.2.4 By Route Of Administration
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.3.1 By Vaccine Type
    • 9.3.2 By Indication
    • 9.3.3 By Age Group
    • 9.3.4 By Route Of Administration
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.4.1 By Vaccine Type
    • 9.4.2 By Indication
    • 9.4.3 By Age Group
    • 9.4.4 By Route Of Administration
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.5.1 By Vaccine Type
    • 9.5.2 By Indication
    • 9.5.3 By Age Group
    • 9.5.4 By Route Of Administration
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.6.1 By Vaccine Type
    • 9.6.2 By Indication
    • 9.6.3 By Age Group
    • 9.6.4 By Route Of Administration
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL INFLUENZA VACCINE INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 GSK Plc
    • 11.2.2 Pfizer Inc
    • 11.2.3 Vaxess Technologies Inc
    • 11.2.4 Merck & Co. Inc
    • 11.2.5 Viatris Inc
    • 11.2.6 Osivax
    • 11.2.7 AstraZeneca Plc
    • 11.2.8 Sinovac Biotech Ltd
    • 11.2.9 CSL Limited
    • 11.2.10 Emergent BioSolutions Inc
    • 11.2.11 Emergex Vaccines Holding Ltd